The reader is cautioned not to place undue reliance on any forward-looking information.
Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information, or to set up an exploration call, visit and Contact Information
#NOVAMIND NEWS PROFESSIONAL#
Synthesis is pioneering models for transformative wellness through professional, clinically-inspired psychedelic experiences and training, providing unprecedented access for people seeking alternative therapies, as well as new modes of study for researchers investigating the effects of psychedelics in a professional setting. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.įounded in 2018, Synthesis is a legal, scientist-backed psychedelic wellness, research and education platform outside of Amsterdam. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Including the Sale Proceeds, Novamind's balance sheet is strengthened with a total of CAN$9,207,945 in cash and short-term investments, and no debt (unaudited figures as at August 10, 2021). Novamind realized gross proceeds of approximately CAN$1,760,000 from the sale of its Strategic Investment in Synthesis ("Sale Proceeds"). "We remain aligned in our common mission to increase access to safe, regulated psychedelic-assisted healing." "Novamind was a strategic investor in Synthesis at an early stage, helping to influence the company's direction and expansion," said Rachel Aidan, Chief Executive Officer of Synthesis. Pursuant to the terms of an agreement between Synthesis and Novamind, Synthesis purchased Novamind's Strategic Investment for €1,200,000 yielding a 60 per cent return on investment. Novamind led Synthesis' seed financing in 2019 with a strategic investment of €750,000 (the "Strategic Investment"). (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company's investment in the Synthesis Institute, a leader in psychedelic retreats and practitioner training programs located in the Netherlands ("Synthesis"). TORONTO, ON / ACCESSWIRE / Aug/ Novamind Inc.